B
ALXN

Barings’s Alexion Pharmaceuticals ALXN Stock Holding History

Barings’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,196
Closed -$1.4M – 657
2020
Q3 		$1.4M Sell
12,196
-2,472
-17% -$267K 0.03% 290
2020
Q2 		$1.32M Hold
14,668
– – 0.04% 250
2020
Q1 		$1.32M Sell
14,668
-2,042
-12% -$200K 0.04% 250
2019
Q4 		$1.79M Buy
16,710
+8,840
+112% +$945K 0.05% 257
2019
Q3 		$771K Hold
7,870
– – 0.02% 423
2019
Q2 		$1.03M Buy
7,870
+4,830
+159% +$623K 0.02% 376
2019
Q1 		$411K Hold
3,040
– – 0.01% 576
2018
Q4 		$296K Sell
3,040
-165
-5% -$19.5K 0.01% 598
2018
Q3 		$446K Hold
3,205
– – 0.01% 644
2018
Q2 		$397K Buy
3,205
+165
+5% +$19.3K 0.01% 696
2018
Q1 		$339K Hold
3,040
– – ﹤0.01% 786
2017
Q4 		$364K Sell
3,040
-2,820
-48% -$343K ﹤0.01% 793
2017
Q3 		$822K Buy
5,860
+2,820
+93% +$383K 0.01% 534
2017
Q2 		$370K Buy
+3,040
New +$354K 0.01% 696
2015
Q3 		– Sell
-2,840
Closed -$513K – 988
2015
Q2 		$513K Sell
2,840
-3,750
-57% -$647K 0.02% 686
2015
Q1 		$1.14M Hold
6,590
– – 0.03% 474
2014
Q4 		$1.22M Buy
6,590
+3,090
+88% +$573K 0.03% 419
2014
Q3 		$580K Sell
3,500
-6,440
-65% -$1.06M 0.01% 631
2014
Q2 		$1.55M Buy
9,940
+4,220
+74% +$666K 0.05% 384
2014
Q1 		$870K Buy
5,720
+3,060
+115% +$487K 0.03% 498
2013
Q4 		$354K Hold
2,660
– – 0.01% 705
2013
Q3 		$309K Sell
2,660
-1,170
-31% -$128K 0.01% 753
2013
Q2 		$353K Buy
+3,830
New +$369K 0.02% 691

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Barings's ALXN Position: Q4 2020 in Review

Barings sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 12,196 shares — an estimated $1.4M sold.

Barings first reported a position in ALXN in Q2 2013 and held it in 23 quarters. The position peaked at $1.79M in Q4 2019. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Barings reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Barings sold 12,196 Alexion Pharmaceuticals shares in Q4 2020, an estimated $1.4M.
  • Barings first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Barings's Alexion Pharmaceuticals position peaked at $1.79M in Q4 2019.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Barings's 13F filing for Q4 2020, filed 16 Feb 2021.